Indeed we recently showed that 5 weeks of SGLT2i treatment in type 2 diabetes patients resulted in ∼90 g of glucose excretion via urine, reduced 24 h glucose levels and increased circulating free fatty acids (FFA) and beta-hydroxybutyrate levels, accompanied by marked adjustments of 24 h energy metabolism that (in part) mimic the effects of calorie restriction, such as increased 24 h fat oxidation, improved metabolic flexibility, and hepatic and adipose tissue insulin sensitivity, while whole-body, and peripheral insulin sensitivity was not affected [6]. Here, INS is linked to type 2 diabetes mellitus.